Theratechnologies Results and Business Updates

 

• Sudocetaxel zendusortide Phase 1 Trial to resume following FDA agreement to amended protocol
   
• Q2 2023 consolidated revenue were affected by specialty pharmacy inventory adjustments, and came in at $17.5 million
   
• FY2023 revenue guidance recast to fall within $82 million and $87 million, or growth in the range of 3% and 9%, as compared to 2022
   
• $5.5 million in additional annualized cost savings measures to be implemented, ensures pathway to reaching positive adjusted EBITDA

https://www.biospace.com/article/releases/theratechnologies-reports-second-quarter-2023-financial-results-and-business-updates/